Canada Pension Plan Investment Board Reduces Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Canada Pension Plan Investment Board lowered its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 42.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 37,000 shares of the biopharmaceutical company's stock after selling 27,000 shares during the quarter. Canada Pension Plan Investment Board owned about 0.06% of Celldex Therapeutics worth $935,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. American Century Companies Inc. grew its holdings in shares of Celldex Therapeutics by 46.5% during the 4th quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock worth $15,376,000 after acquiring an additional 193,093 shares during the period. Renaissance Technologies LLC bought a new position in Celldex Therapeutics in the fourth quarter worth $3,452,000. Sovran Advisors LLC purchased a new position in Celldex Therapeutics during the fourth quarter valued at $2,867,000. Fisher Asset Management LLC lifted its position in Celldex Therapeutics by 20.9% during the fourth quarter. Fisher Asset Management LLC now owns 452,497 shares of the biopharmaceutical company's stock valued at $11,435,000 after buying an additional 78,145 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Celldex Therapeutics by 140.7% during the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock valued at $4,431,000 after buying an additional 76,207 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. The Goldman Sachs Group lowered their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Canaccord Genuity Group assumed coverage on Celldex Therapeutics in a research note on Monday. They set a "buy" rating and a $64.00 price objective for the company. UBS Group initiated coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 target price on the stock. Finally, Morgan Stanley initiated coverage on Celldex Therapeutics in a report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price target for the company. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $55.30.

Celldex Therapeutics Trading Down 0.5 %

NASDAQ:CLDX traded down $0.10 during mid-day trading on Wednesday, reaching $20.83. The company's stock had a trading volume of 684,578 shares, compared to its average volume of 884,828. The stock has a market cap of $1.38 billion, a P/E ratio of -8.11 and a beta of 1.59. The firm's fifty day moving average price is $19.11 and its two-hundred day moving average price is $23.34. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. The firm had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.